Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

Background: The endothelin receptor antagonist atrasentan reduced the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease (CKD) in the SONAR (Study of Diabetic Nephropathy with Atrasentan) trial, although with a numerically higher incidence of heart failure (H...

Full description

Bibliographic Details
Main Authors: Bakris, G.L (Author), Correa-Rotter, R. (Author), de Zeeuw, D. (Author), Heerspink, H.J.L (Author), Hou, F.-F (Author), Januzzi, J.L (Author), Kitzman, D.W (Author), Kohan, D.E (Author), Kolansky, D.M (Author), Koomen, J. (Author), Makino, H. (Author), McMurray, J.J.V (Author), Parving, H.-H (Author), Perkovic, V. (Author), Smeijer, J.D (Author), Tobe, S. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
atrasentan
chronic kidney disease
endothelin receptor antagonist
heart failure
type 2 diabetes mellitus
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items